Hypothesis

Circulating indole-3-propionic acid (IPA) modulates the rate of epigenetic aging in a sex-dependent manner by activating hepatic SIRT1, which in turn remodels DNA methylation at GrimAge-associated CpG sites; this effect is amplified in females due to estrogen-mediated SIRT1 up-regulation and attenuated in individuals lacking functional FUT2-dependent secretor status.

Mechanistic Rationale

IPA reaches the portal circulation and accumulates in hepatocytes where it acts as a ligand for SIRT1, enhancing its deacetylase activity [4]. SIRT1 deacetylates histone H3K9 and transcription factors such as NF-kB, leading to a chromatin state that favors maintenance of methylation patterns linked to longevity pathways [1]. Estrogen receptors alpha and beta directly increase SIRT1 expression, providing a mechanistic basis for the observed genotype- and sex-specific lifespan extension of IPA in Drosophila [4]. In contrast, acute high-dose IPA can overload mitochondrial respiration, reducing SIRT1 activation and promoting oxidative stress [5], which explains the biphasic effect on cardiomyocyte respiration. Gut microbiota composition determines IPA production; FUT2 secretor status influences mucosal glycan availability and thus the abundance of IPA-producing Clostridia, creating a host-genetic layer that modulates circulating levels [2].

Testable Predictions

1. In a balanced cohort of older adults, baseline serum IPA will correlate negatively with GrimAge acceleration, and the slope of this association will be significantly steeper in females than in males (p < 0.01).
2. Oral IPA supplementation (20 mg/kg x 3x/wk for 12 weeks) will reduce GrimAge acceleration by >= 0.5 years in females but produce a negligible change (< 0.1 years) in males, with the difference surviving adjustment for baseline IPA, BMI, and medication use.
3. The supplementation effect will be absent in participants classified as FUT2 non-secretors, confirming that host-genetic constraints on microbial IPA synthesis limit the metabolite’s bioavailability.
4. Hepatic SIRT1 activity, measured by peripheral blood mononuclear cell deacetylation of p53, will mediate >= 40% of the IPA-GrimAge relationship in females, as shown by mediation analysis.

Experimental Design

• Population: 300 community-dwelling adults aged 65-80, stratified by sex (150 F/150 M) and FUT2 status (secretor vs non-secretor) using saliva genotyping.
• Baseline: Collect fasting serum for IPA LC-MS/MS, whole-blood DNA for Illumina EPIC array (to compute GrimAge, PhenoAge, and DunedinPoAm), and PBMCs for SIRT1 activity assay.
• Intervention: Randomized, double-blind, placebo-controlled trial. Participants receive either microencapsulated IPA (20 mg/kg) or matched placebo three times weekly for 12 weeks.
• Outcomes: Primary – change in GrimAge acceleration (Delta GrimAge = post minus pre). Secondary – changes in PhenoAge, DunedinPoAm, serum cytokines (IL-6, TNF-alpha), and SIRT1 activity.
• Analysis: Linear mixed models with random intercept for site, fixed effects for treatment, sex, FUT2 status, and their interactions. Mediation analysis using structural equation modeling to test SIRT1 as mediator.

Potential Pitfalls and Alternatives

If IPA fails to alter GrimAge, we will assess whether the metabolite reaches hepatic concentrations sufficient for SIRT1 activation by measuring hepatic-derived biomarkers (e.g., fibroblast growth factor-21) in serum. A null result could indicate that IPA’s longevity effects in rodents act primarily through extra-hepatic pathways (e.g., intestinal barrier improvement) rather than direct epigenetic remodeling, prompting a shift to gut-permeability endpoints as primary outcomes.